Ginkgo Bioworks Holdings, Inc. DNA
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -251.03M | -290.80M | -304.39M | -312.76M | -339.55M |
| Total Depreciation and Amortization | 33.62M | 35.30M | 38.14M | 40.16M | 42.15M |
| Total Amortization of Deferred Charges | 17.20M | 17.10M | 17.20M | 17.20M | 17.20M |
| Total Other Non-Cash Items | 99.09M | 107.99M | 133.65M | 127.83M | 132.11M |
| Change in Net Operating Assets | -65.86M | -39.83M | -50.82M | -43.49M | -17.72M |
| Cash from Operations | -166.99M | -170.24M | -166.22M | -171.06M | -165.82M |
| Capital Expenditure | -6.56M | -4.56M | -1.98M | -7.67M | -21.37M |
| Sale of Property, Plant, and Equipment | 574.00K | 574.00K | 574.00K | 574.00K | 57.00K |
| Cash Acquisitions | -- | -- | -- | -- | 0.00 |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 111.20M | 60.49M | -17.07M | -233.20M | -327.16M |
| Cash from Investing | 105.22M | 56.50M | -18.47M | -240.29M | -348.47M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -44.00K | -68.00K | -166.00K | -354.00K | -532.00K |
| Issuance of Common Stock | 32.95M | 36.52M | 19.47M | 19.47M | 10.32M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.79M | -1.90M | -1.34M | -1.34M | -355.00K |
| Cash from Financing | 31.12M | 34.55M | 17.96M | 17.78M | 9.43M |
| Foreign Exchange rate Adjustments | -232.00K | -145.00K | -2.00K | 201.00K | 280.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -30.88M | -79.34M | -166.74M | -393.37M | -504.58M |